Please login to the form below

Not currently logged in
Email:
Password:

IBD

This page shows the latest IBD news and features for those working in and with pharma, biotech and healthcare.

The impact of COVID-19 on the fight against AMR

The impact of COVID-19 on the fight against AMR

and the invasive bacterial disease (IBD) incidence, using parameters based on the commensal community bacterium Streptococcus pneumoniae (S pneumoniae). ... It was observed that lockdown ‘substantially reduces’ the number of annual cases of resistant

Latest news

More from news
Approximately 12 fully matching, plus 37 partially matching documents found.

Latest Intelligence

  • Setting up for success in a post-Brexit, post-pandemic Britain Setting up for success in a post-Brexit, post-pandemic Britain

    With IBD widely considered an ‘invisible disease’, patients cannot afford to be pushed into the background any longer. ... and running, ahead of our UK marketing authorisation in IBD, through our partnership with Gilead.

  • Gut instincts lead Takeda to GI pipeline success Gut instincts lead Takeda to GI pipeline success

    It has been a game changer for IBD patients and the EMA decision means that they have greater choice. ... Projects that address gut inflammation beyond IBD are focused on coeliac disease, acute pancreatitis and short bowel syndrome.

  • Case study: Logic IBD Nurse Education Day and Recognition Event Case study: Logic IBD Nurse Education Day and Recognition Event

    The solution was a dual-aspect meeting: The ‘LOGIC IBD Nurse Education Day and Recognition Event’. ... IBD nurses had limited support with personal development and raising their profile within their hospital/Trust.

  • Case study: IBD Registry Roadshow Case study: IBD Registry Roadshow

    It was originally planned to run alongside a successful national IBD Audit programme managed by the Royal College of Physicians (RCP). ... In 2015 NHS England announced it was pulling the Audit funding and recommended that future audits be incorporated

  • Deal Watch February 2017 Deal Watch February 2017

    The deal also includes a licence to AKB-5169 (formerly JNJ5169), an oral, preclinical stage compound for inflammatory bowel disease (IBD). ... Joint venture. 286.3. Janssen/ Akebia Therapeutics. HIF-targeting candidates inc AKB-5169 for IBD (pc) plus

More from intelligence
Approximately 1 fully matching, plus 12 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 4 fully matching, plus 21 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Flu
Influenza – the risk to vulnerable populations
Why we can't get complacent about flu vaccination...
dementia
Alzheimer’s Research UK highlights socio-economic inequalities in dementia risk
The charity aims to improve the number of women participating in dementia research and grow awareness of dementia risk factors...
Data security
Concerns about data security are building a strong case for clinical mobility in EMEA
Electronic medical records have transformed the storage of sensitive information but how can the healthcare sector continue to protect patient and staff data?...